Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 11,684 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 11,684 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total value of $89,032.08. Following the completion of the transaction, the insider directly owned 277,964 shares in the company, valued at approximately $2,118,085.68. This represents a 4.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Peter Rahmer also recently made the following trade(s):

• On Wednesday, January 28th, Peter Rahmer sold 1,354 shares of Relay Therapeutics stock. The shares were sold at an average price of $8.45, for a total value of $11,441.30.

Relay Therapeutics Trading Up 0.8%

RLAY stock traded up $0.06 during midday trading on Thursday, hitting $7.71. The stock had a trading volume of 1,788,553 shares, compared to its average volume of 2,246,533. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -4.41 and a beta of 1.55. Relay Therapeutics, Inc. has a 52 week low of $1.77 and a 52 week high of $9.04. The stock has a 50-day simple moving average of $7.93 and a 200 day simple moving average of $5.93.

Relay Therapeutics (NASDAQ:RLAY) last posted its earnings results on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.04). On average, equities analysts forecast that Relay Therapeutics, Inc. will post -2.55 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on RLAY shares. Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price for the company in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. Finally, Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $6.00 to $13.00 in a research report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC increased its holdings in shares of Relay Therapeutics by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $34,000 after acquiring an additional 5,000 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new position in shares of Relay Therapeutics in the 2nd quarter valued at approximately $35,000. May Hill Capital LLC acquired a new stake in Relay Therapeutics during the 2nd quarter worth approximately $38,000. Focus Partners Advisor Solutions LLC bought a new position in Relay Therapeutics in the second quarter valued at approximately $39,000. Finally, Quadrant Capital Group LLC boosted its holdings in shares of Relay Therapeutics by 245.1% in the second quarter. Quadrant Capital Group LLC now owns 11,791 shares of the company’s stock valued at $41,000 after buying an additional 8,374 shares during the period. 96.98% of the stock is owned by institutional investors and hedge funds.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.